Biotech Values

[mcbio]

I'm looking at HGSI ahead of the March 10 FDA decision on Benlysta.

I'm concerned about possible/probable label restrictions and their effect on the potential revenue from the drug. Also, IMO the $25+ current share price is not cheap and I wonder how much approval pop is left.

Any thoughts are greatly appreciated, TIA.

It's trading near a $5B market cap in front of a critical binary event for a drug indication where we have had no FDA guidance to rely on in a long time. No way in the world I'd touch it, but I've been wrong on HGSI before. That said, I'd imagine there are a ton of expectations already baked into the share price and if you have any concerns about regulatory risk at all, it probably makes sense to be careful.